VXLVaxil Bio Ltd.
0.2300CAD0.00%Mkt Cap: 916324 CADP/E: 1.28Last update: 2026-05-29
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vacc…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap916.32K CAD
Enterprise Value320.08K CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)522.00K CAD
Revenue/Share—
Last Price0.2300 CAD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)1.28
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.95
EPS (TTM)0.18
EPS (Forward)—
52W Range
0.130051% of range0.3250
52W High0.3250 CAD
52W Low0.1300 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE38.24%
ROA38.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-158.00K CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-7.16%
Net Debt-447.00K CAD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio75.38
Quick Ratio57.38
Book Value/Sh0.2430 CAD
Cash/Share0.1630 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.98M
Float2.59M
Insiders5.61%
Institutions0.00%
Short Interest
Short Ratio0.4d
Short % Out.0.03%
Shares Short547
Short (prev mo.)6
Technical
SMA 500.2111 (+9.0%)
SMA 2000.1704 (+35.0%)
Beta-1.26
S&P 52W Chg27.70%
Avg Vol (30d)2.47K
Avg Vol (10d)475
Technical Indicators
RSI (14)46.6
MACD0.0013
MACD Signal0.0086
MACD Hist.-0.0073
BB Upper0.2983 CAD
BB Middle0.2522 CAD
BB Lower0.2062 CAD
BB Width36.51%
ATR (14)0.0045 CAD
Vol Ratio (20d)19.07x